Boniva Ad Campaign Prompts Procter & Gamble/Sanofi-Aventis Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
Procter & Gamble/Sanofi-Aventis allege that Roche and GSK's campaign for Boniva is misleading because it fails to state that Boniva is not approved for treatment of nonspinal fractures.
You may also be interested in...
Class Effect Is Good Enough For Boniva Ads, Judge Rules
Roche/GSK advertising is not false despite lack of specific trial results for nonvertebral fractures, court says in ruling against P&G/Sanofi.
Class Effect Is Good Enough For Boniva Ads, Judge Rules
Roche/GSK advertising is not false despite lack of specific trial results for nonvertebral fractures, court says in ruling against P&G/Sanofi.
Roche Plans Boniva Ad Changes To Energize “Static” Script Growth
Swiss drug maker’s new strategy for the osteoporosis therapy will include Fosamax comparison data, new spokesperson.